Treasury 10-year note yields reached a three-month high after a report showed durable-goods orders rose in November more than forecast, boosting the case for the Federal Reserve to slow bond-buying further.
U.S. government securities fell for a second day. The Federal Open Market Committee said after its Dec. 17-18 policy meeting it will cut its monthly asset purchases by $10 billion to $75 billion starting in January. Treasuries reached the cheapest level relative to stocks in 3 1/2 years Monday.
“The durable goods number was strong, a good indication that the economies contributors to growth are expanding,” said Adrian Miller, director of fixed-income strategies at GMP Securities. “One month doesn't make a trend, but it's something the market wanted to see and confirms what the Fed has been seeing that gave confidence for their taper.”
Best Industrial Conglomerate Stocks To Invest In Right Now: CF Industries Holdings Inc. (CF)
CF Industries Holdings, Inc., through its subsidiary, CF Industries, Inc., manufactures and distributes nitrogen and phosphate fertilizer products, serving agricultural and industrial customers worldwide. It operates in two segments, Nitrogen and Phosphate. The Nitrogen segment principally offers ammonia, granular urea, urea ammonium nitrate solution, urea liquor, diesel exhaust fluid, and aqua ammonia. The Phosphate segment primarily offers diammonium phosphate and monoammonium phosphate. The company also owns 50% interests in the GrowHow UK Limited, a nitrogen products producer in the United Kingdom; Point Lisas Nitrogen Limited, an ammonia producer; and KEYTRADE AG, a global fertilizer trading company. CF Industries Holdings� customers include cooperatives and independent fertilizer distributors primarily in the midwestern United States. The company was founded in 1946 and is headquartered in Deerfield, Illinois.
Advisors' Opinion:- [By Alex Planes]
Fool contributor GC Mays notes that nitrogen-focused fertilizer producer CF Industries (NYSE: CF ) followed PotashCorp and Mosaic's (NYSE: MOS ) lead by posting lower revenues and earnings on declining prices and volume, which stemmed from a huge decline in corn prices. However, CF Industries has agreed to a deal with Mosaic under which it will supply 600,000 to 800,000 tons of ammonia annually for up to 15 years, which could undermine PotashCorp's already weakened position. In an effort to diversify from its hard-hit potash business with more profitable, Mosaic also recently purchased CF Industries' phosphate business for $1.4 billion. These consolidative moves by two major competitors could bode ill for PotashCorp, which may need to find a partner as well.
- [By Neha Chamaria]
Clearly, of the three companies, PotashCorp and Mosaic are likely to be hit the hardest if India's fertilizer imports decline. Agrium deals primarily in nitrogen, and nitrogen-centric companies depend more on the domestic market for sales. That's also the reason why CF Industries (NYSE: CF ) didn't find itself on my list of companies that need to worry if things in India get ugly. Phosphate made up 17% of CF's revenue last year; the rest came from nitrogen. Also, only 6.5% of CF's sales last year came from markets outside the U.S. and Canada.
- [By Ben Levisohn]
Among the other material stocks joining Goldcorp among Barclays’ top picks for 2014: Freeport-McMoRan Copper & Gold (FCX) and�CF Industries�(CF). Freeport-McMoRan has gained 0.9% to $34.95 and CF Industries has dropped 0.6% to $230.10.
- [By Roberto Pedone]
CF Industries (CF) is a manufacturer and distributor of nitrogen and phosphate fertilizer products in North America. This stock closed up 11.7% at $202.32 in Monday's trading session.
Monday's Volume: 5.65 million
Three-Month Average Volume: 899,814
Volume % Change: 484%Shares of CF soared higher on Monday after billionaire Dan Loeb's Third Point Management revealed a position in the firm in its quarterly investment letter. Loeb told investors the company trades at an unwarranted discount to its peers and that it expects management to deliver a much larger dividend to shareholders.
From a technical perspective, CF soared higher here back above both its 50-day at $184.76 and its 200-day at $198.52 with monster upside volume. This move pushed shares of CF into breakout territory, since the stock took out some key overhead resistance levels at $187.60 to $191.52 and then above $196.25 to $196.97. Shares of CF are now quickly moving within range of triggering another major breakout trade. That trade will hit if CF manages to take out some past overhead resistance at $208.17 with high volume.
Traders should now look for long-biased trades in CF as long as it's trending above its 200-day at $198.52 or above $197 and then once it sustains a move or close above Monday's high of $202.77 to $208.17 with volume that hits near or above 899,814 shares. If that breakout triggers soon, then CF will set up to re-test or possibly take out its next major overhead resistance levels at $220 to $225.
Keep in mind that CF is set to report earnings on Aug. 6 after the market close. Look to play that breakout before and then after earnings, once you know that the stock is reacting positively to the numbers.
5 Best Cheapest Stocks To Buy Right Now: South Jersey Industries Inc.(SJI)
South Jersey Industries, Inc., through its subsidiaries, engages in the purchase, transmission, and sale of natural gas for residential, commercial, and industrial customers. It also sells natural gas and pipeline transportation capacity on a wholesale basis to various customers on the interstate pipeline system, as well as transports natural gas purchased directly from producers or suppliers to their customers. In addition, it markets natural gas storage, commodity, and transportation assets on a wholesale basis for energy marketers, electric and gas utilities, and natural gas producers in the mid-Atlantic, Appalachian, and southern regions of the United States. Further, the company develops and operates energy-related projects, which provide cooling, heating, and emergency power; and operates landfill gas-fired electric production facilities and solar projects. Additionally, it provides services for the acquisition and transportation of natural gas and electricity for re tail end users; markets total energy management services; installs and services residential and light commercial HVAC systems; provides plumbing services; and services appliances, as well as offers meter reading services. As of December 31, 2010, the company served 347,725 residential, commercial, and industrial customers primarily in southern New Jersey. The company was founded in 1910 and is headquartered in Folsom, New Jersey.
Advisors' Opinion:- [By Marc Bastow]
Energy services holding company South Jersey Industries (SJI) raised its quarterly dividend 6.7% to 47.25 cents per share, payable on Dec. 27 to shareholders of record as of Dec. 10. The increase marks the 15th consecutive increase to the annual dividend.
SJI Dividend Yield: 3.41%
5 Best Cheapest Stocks To Buy Right Now: Synergy Pharmaceuticals Inc (SGYP)
Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.
As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.
The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.
Advisors' Opinion:- [By Sean Williams]
Finally, Synergy Pharmaceuticals (NASDAQ: SGYP ) may have had the wildest week of them all. Synergy's share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company's midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn't return the favor to shareholders by -- the very next day, mind you ��announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.
- [By Monica Gerson]
Breaking news
Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
5 Best Cheapest Stocks To Buy Right Now: Sigma Labs Inc (SGLB)
Sigma Labs, Inc., incorporated on December 23, 1985, has two wholly-owned subsidiaries, B6 Sigma, Inc. and Sumner & Lawrence Limited (dba Sumner Associates). B6 Sigma, Inc. (B6 Sigma) develops precision manufacturing solutions and advanced materials technologies, as well as Reasearch and Development solutions for first-tier integrators and other commercial firms worldwide. Sumner Associates provide consultants to Federal government and commercial clients seeking productive solutions for development technologies. As of December 31, 2012, the Company is engaged in a range of activities, in which it seek to commercialize technologies and products in the industry sectors, which include in process quality assurance for manufacturing; aerospace and defense manufacturing; additive manufacturing; active protection systems for defending light armored vehicles; advanced materials for munitions; advanced materials for sporting goods; advanced manufacturing technologies, and dental implant and biomedical prosthetics technologies.
Sumner & Lawrence Limited (Sumner), based in Santa Fe, New Mexico, provides consulting services to the public sector, especially with regard to emerging technologies and alternative applications of established technologies. Sumner holds ongoing contracts with government agencies and the appropriate levels of security clearance for those contracts. Sumner's clients include the State Department, the Department of Defense, the Department of Energy, various military services and affiliated agencies, the National Laboratories, and contractors to these organizations.
Advisors' Opinion:- [By James E. Brumley]
For veteran traders who've kept tabs on Sigma Labs Inc. (OTCMKTS:SGLB) over the past three months or so, it may be surprising to hear someone suggest it as a buy. Like so many other stocks of its ilk have done since the beginning of the organized market, SGLB went from (proverbially) zero to hero between late May and mid-July with a move from $0.025 to a peak of $0.118 only to fall back to the $0.04 level a couple of weeks later. It's the relatively common "one hit wonder", and if Sigma Labs followed the usual pattern of other small stocks that burned brilliantly for a few days, we wouldn't see anything particularly bullish from SGLB for a few months, if not years.
No comments:
Post a Comment